TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (loss)
(U.S. dollars in millions)
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net income (loss) | $(390) | $77 | $(1,684) | $(1,082) |
| Other comprehensive income (loss), net of tax: | ||||
| Currency translation adjustment | 174 | (255) | (94) | (173) |
| Unrealized gain (loss) from derivative financial instruments, net | 7 | 7 | 21 | 19 |
| Unrealized loss on defined benefit plans | (1) | (1) | (2) | (2) |
| Total other comprehensive income (loss) | 180 | (249) | (75) | (156) |
| Total comprehensive income (loss) | (210) | (172) | (1,759) | (1,238) |
| Comprehensive income (loss) attributable to non-controlling interests | 114 | (8) | (268) | (144) |
| Comprehensive income (loss) attributable to Teva | $(324) | $(164) | $(1,491) | $(1,094) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.